Concepedia

Author

Radosław Polański

AstraZeneca (United Kingdom)ORCID

Also Known As

Polanski, Radoslaw, R Polanski, R. Polanski, Radoslaw Polanski, Radosław Polański, Radosław Polański

80

Publications

1.9K

Citations

16

H-Index

39

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (United States)University of LiverpoolCancer Research UK Manchester InstituteUniversity of Manchester
RP

About

Radosław Polański is an author at AstraZeneca (United Kingdom) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

783

2

Natural Sciences

3

3

44

3

Biochemistry

2

2

31

4

Biomolecular Engineering

2

2

26

5

Cell Biology

2

2

702

Radosław Polański

×

19

Publications

1.8K

Citations

16

H-Index

YearCitations

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer

Cassandra L. Hodgkinson, Christopher J. Morrow, Yaoyong Li,

Nature Medicine

2014

682

Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer

Radosław Polański, Cassandra L. Hodgkinson, Alberto Fusi,

Clinical Cancer Research

2013

345

Vasculogenic mimicry in small cell lung cancer

Stuart C. Williamson, Robert Metcalf, Francesca Trapani,

Nature Communications

2016

237

Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist

James S. Scott, Amber Balazs, Bernard Barlaam,

Journal of Medicinal Chemistry

2020

109

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Mandy Lawson, Natalie Cureton, Susana R�os,

Cancer Research

2023

54

MDM2 Regulates Dihydrofolate Reductase Activity through Monoubiquitination

Maria Maguire, Paul C. Nield, Timothy Devling,

Cancer Research

2008

50

Tricyclic Indazoles—A Novel Class of Selective Estrogen Receptor Degrader Antagonists

James S. Scott, Andrew Bailey, David Buttar,

Journal of Medicinal Chemistry

2019

37

Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy

Aidan P. Noon, Radosław Polański, Ashraf Y. El‐Fert,

British Journal of Urology

2011

35

MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility

Radosław Polański, Maria Maguire, Paul C. Nield,

Carcinogenesis

2011

27

Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors

James T. Lynch, Urszula M. Polanska, Ursula Hancox,

Molecular Cancer Therapeutics

2018

26

Page 1